Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 3/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10116268 | 1.00 | CRHBP (0.40) | CRHBPCRHR2KMT2ATHRBLMNA | |
| SCHEMBL10116206 | 0.90 | CRHBP (0.43) | CRHBPCRHR2KMT2ATHRBLMNA | |
| SCHEMBL10116266 | 0.88 | CRHBP (0.41) | CRHBPCRHR2KMT2ATHRBLMNA | |
| SCHEMBL10133814 | 0.88 | CRHBP (0.41) | CRHBPCRHR2KMT2ATHRBLMNA | |
| SCHEMBL10134522 | 0.88 | KMT2A (0.39) | CRHBPCRHR2KMT2ATHRBLMNA | |
| SCHEMBL10116548 | 0.88 | KMT2A (0.39) | CRHBPCRHR2KMT2ATHRBLMNA | |
| SCHEMBL13204920 | 0.88 | KMT2A (0.39) | CRHBPCRHR2KMT2ATHRBLMNA | |
| SCHEMBL17090454 | 0.84 | KDM4E (0.35) | CRHBPCRHR2KMT2ALMNAKDM4E | |
| SCHEMBL13565281 | 0.84 | KDM4E (0.35) | CRHBPCRHR2KMT2ALMNAKDM4E | |
| SCHEMBL10116205 | 0.84 | LMNA (0.47) | CRHBPCRHR2KMT2ATHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | CRHBP 256/4885CRHR2 13/4885KMT2A 2768/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | CRHBP 247/4885CRHR2 12/4885KMT2A 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.